Aschermann M, Horák J, Linhart A, Aschermann O
II. interní klinika 1. LF UK a VFN, Praha.
Cas Lek Cesk. 2004;143(2):71-4.
Remodelling of the left ventricle after myocardial infarction is a major cause of the heart failure development with possible death. Despite application of pharmacological, catheter and surgical interventions and the use of new mechanical devices, the myocardium lost during myocardial infarction cannot be regenerated. Implantation of bone-marrow stem cells into the heart might be a new method to restore myocardial viability. In animal experiments, attempts to replace fibrotic zone by transplanting stem cells have regularly succeeded in reconstituting myocardial structure--cardiomyocytes and capillary vessels. Repair of myocardium using bone-marrow derived multipotent stem cells was shown in experimental and in the first few clinical studies. Current status of our knowledge about the use of stem cells in the myocardial regeneration is described in this article, as well as the cautions, which are necessary during early period of this mode of treatment in humans.
心肌梗死后左心室重构是心力衰竭发展并可能导致死亡的主要原因。尽管应用了药物、导管和外科干预措施,以及使用了新型机械装置,但心肌梗死期间丧失的心肌无法再生。将骨髓干细胞植入心脏可能是恢复心肌活力的一种新方法。在动物实验中,通过移植干细胞替代纤维化区域的尝试经常成功地重建了心肌结构——心肌细胞和毛细血管。实验研究和最初的一些临床研究表明,使用骨髓来源的多能干细胞可修复心肌。本文描述了我们目前对干细胞用于心肌再生的了解情况,以及在人类进行这种治疗方式的早期阶段所需注意的事项。